Literature DB >> 28441041

The Child Network for Parents to Track Their Child's Mood and Behavior.

Robert M Post1,2, Michael Rowe2, Dana Kaplan3, Robert Findling3.   

Abstract

INTRODUCTION: A wide range of psychiatric disorders are common in young children, especially in those at high risk because of a parent with a unipolar or bipolar mood disorder in the United States. Yet in part because most children are seen in primary care, these illnesses are often not recognized or treated in a timely fashion. To begin to address this problem, we started the Child Network.
METHODS: The Child Network is for parents of children age 2-12 with mood or behavioral symptoms or at high risk for them. The parents rate the severity of symptoms of depression, anxiety, attention-deficit/hyperactivity disorder (ADHD), oppositional behavior, and mania on a once a week basis on a secure website under a Johns Hopkins Intramural Review Board (IRB)-approved protocol. These ratings can then be printed out along with any treatments given to aide in visualization of symptom course. A demographics form, which includes diagnoses given to the child in the community, and a symptom checklist are filled out upon Network entry. We report on the retrospective diagnoses and prospective treatment of the first 65 parents to join the Network.
RESULTS: The most common diagnoses were anxiety disorders and ADHD followed by disruptive behavioral disorders and bipolar spectrum disorders. Prospective ratings of two or more consecutive weeks of moderate to severe rating in any of the five symptom domains paralleled these diagnoses given in the community. Atypical antipsychotics, anticonvulsant mood stabilizers, and medications for ADHD were among the most widely used drugs. An illustrated example of symptom course is presented. DISCUSSION: Many children continued to show substantial symptom severity despite treatment with an average of 2.2 medications. The Child Network provides a useful longitudinal approach to visualize the course of symptoms, which should help lead to earlier and more effective treatment.

Entities:  

Keywords:  ADHD; anxiety; childhood onset bipolar disorder; depression; pharmacological treatment

Mesh:

Year:  2017        PMID: 28441041     DOI: 10.1089/cap.2017.0002

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  5 in total

1.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

Review 2.  Outcomes Accountability Systems for Early Childhood Disruptive Behaviors: A Scoping Review of Availability.

Authors:  Helen Fan Yu-Lefler; Jill Marsteller; Anne W Riley
Journal:  Adm Policy Ment Health       Date:  2022-04-25

3.  Clinician-Identified Factors in Success of Parent-Directed Behavioral Therapy for Children's Tantrums.

Authors:  Helen Fan Yu-Lefler; Steven Lindauer; Anne W Riley
Journal:  Adm Policy Ment Health       Date:  2021-07-28

Review 4.  The Challenges of Children with Bipolar Disorder.

Authors:  Robert M Post; Heinz Grunze
Journal:  Medicina (Kaunas)       Date:  2021-06-11       Impact factor: 2.430

Review 5.  Toward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data.

Authors:  Robert M Post; Benjamin I Goldstein; Boris Birmaher; Robert L Findling; Benicio N Frey; Melissa P DelBello; David J Miklowitz
Journal:  J Affect Disord       Date:  2020-03-06       Impact factor: 4.839

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.